National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Lenvatinib (Kisplyx®) is Indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.

Rapid Review

Commenced Completed Outcome
05/05/2017 18/05/2017 Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.